CytomX to Present at Upcoming Healthcare Conferences

SOUTH SAN FRANCISCO, Calif., March 05, 2019 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on our Probody™ therapeutic technology platform, announced today that members of its senior management team will participate at the following healthcare conferences in March.

Cowen 39th Annual Health Care Conference  

Date: Monday, March 11, 2019 Time: 1:30 p.m. – 2:00 p.m. EST Location: Boston, Massachusetts

Barclays Global Healthcare Conference

Date: Tuesday, March 12, 2019 Time: 2:05 p.m. – 2:35 p.m. EST Location: Miami, Florida

Live audio webcast of theses presentations will be available through the “Investors & News” section of CytomX's website. An archived replay will be available for 90 days following the event.

About CytomX Therapeutics

CytomX Therapeutics is a clinical-stage oncology-focused biopharmaceutical company pioneering a novel class of investigational antibody therapeutics based on its Probody™ therapeutic technology platform. Probody therapeutics are designed to exploit unique conditions of the tumor microenvironment to more effectively localize antibody binding and activity while minimizing activity in healthy tissues. CytomX and its partners have four programs in the clinic.  The Company’s clinical stage pipeline includes cancer immunotherapies against clinically-validated targets, including a PD-L1-targeting Probody therapeutic wholly owned by CytomX (CX-072) and a CTLA-4-targeting Probody therapeutic partnered with Bristol Myers Squibb (BMS-986249). The clinical stage pipeline also includes first-in-class Probody drug conjugates against highly attractive targets including a CD166-targeting Probody drug conjugate wholly owned by CytomX (CX-2009), and a CD71-targeting Probody drug conjugate partnered with AbbVie (CX-2029). CD166 and CD71 are among cancer targets that are considered to be inaccessible to conventional antibody drug conjugates due to their presence on many healthy tissues. In addition to its wholly owned programs, CytomX has strategic collaborations with AbbVie, Amgen, Bristol-Myers Squibb Company and ImmunoGen, Inc. For more information, visit www.cytomx.com.

Contact: Investors and Media: Christopher Keenan VP, Investor Relations and Corporate Communications [email protected] 650-383-0823

Source: CytomX Therapeutics Inc.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Facultative & Treaty Reinsurance Solutions for Engineering Projects To Expand
• Opifex-Synergy Issues $450 Million of Senior Secured Notes due 2034
• CORRECTION FROM SOURCE: Mobile-health Network Solutions Expands into Cybersecurity with Skylink-Contfinity Partnership, Launching OtterSG Bundled Solution for Clinics in Singapore